- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Securing the Pharma Supply Chain: Latest Initiatives
The problem of supply-chain security has taken center stage with a number of recent initiatives, writes Patricia Van Arnum.
By Patricia van Arnum
Although the problem of counterfeit drugs traditionally has centered on solid dosage drugs, recent drug shortages for injectable cancer medications have triggered concerns over counterfeit versions of these types of drugs. In January 2012, FDA advised that current shortages of injectable cancer medications may present an opportunity for introduction of non-FDA approved products into the drug supply. FDA advised healthcare providers to obtain and use only FDA- approved injectable cancer medications purchased directly from the manufacturer or from wholesale distributors licensed in the United States.
This article was also published in our US sister publication Pharmaceutical Technology and can be read here.
FTC, HHS Launch Investigation into Role of GPOs, Wholesalers in Ongoing Generic Drug Shortages
February 15th 2024The Federal Trade Commission and Department of Health and Human Services are examining the practices of group purchasing organizations and drug wholesalers and the role they may play in triggering shortages of generic medications.
Sanofi Announces New Reservation Program to Mitigate Shortages of RSV Vaccine for Next Season
February 2nd 2024Beyfortus (nirsevimab-alip), a monoclonal antibody that protects against respiratory syncytial virus-associated lower respiratory tract disease, experienced higher than anticipated demand that led to shortages during the 2023-2024 season.
